Neil Patel, MD
Neurology · Mt Pleasant, SCNPI 1477992063
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. SK Life Science, Inc. accounts for 76.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $14,896 and has fallen 68.8% since, to $4,649 in 2025.
Across 117 payments — averaging $207.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$19K
- Livanova USA, Inc.$2K
- Pfizer$2K
- Eisai Inc.$484
- UCB, Inc.$444
- Neurelis, Inc.$317
- plus $1K from 13 others
Across 12 payments — averaging $3021.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$36K
What the payments were for
- Consulting fees$1,5256%
- Speaking & faculty fees$14,02558%
- Travel & lodging$1,9788%
- Food & beverage$6,73128%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 56 | $18,557 |
| Livanova USA, Inc. | 10 | $1,795 |
| Pfizer | 4 | $1,544 |
| Eisai Inc. | 4 | $484 |
| UCB, Inc. | 14 | $444 |
| Neurelis, Inc. | 6 | $317 |
| TG Therapeutics, Inc. | 6 | $242 |
| AbbVie | 5 | $183 |
| Sunovion Pharmaceuticals Inc. | 1 | $154 |
| Abbott | 1 | $140 |
| Boston Scientific | 1 | $111 |
| Jazz Pharmaceuticals Inc. | 1 | $110 |
| Neuropace, Inc. | 2 | $84 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$15,393
- NURTEC ODT$1,525
- VNS Therapy$1,522
- Fycompa$484
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$150
- BRIUMVI$147
- AVEIR$140
- Cenobamate$125
- VYALEV$124
- VALTOCO$124
- WATCHMAN Access System$111
- Epidiolex$110
How this compares
$24,275 in reported general payments places this provider in the 85th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 55 | $239,638 |
| XcopriCenobamate | 133 | $175,819 |
| BriviactBrivaracetam | 69 | $117,740 |
| VimpatLacosamide | 21 | $74,562 |
| AptiomEslicarbazepine Acetate | 33 | $54,822 |
| Lacosamide | 344 | $38,373 |
| Trokendi XrTopiramate | 13 | $31,022 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $25,177 |
| QuliptaAtogepant | 16 | $18,148 |
| Nurtec OdtRimegepant Sulfate | 11 | $16,093 |
| FycompaPerampanel | 11 | $14,651 |
| Lamotrigine ErLamotrigine | 64 | $13,432 |
| LamictalLamotrigine | 13 | $13,281 |
| Levetiracetam | 410 | $12,507 |
| NayzilamMidazolam | 16 | $11,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $444 | $204,127106 claims |
| SK Life Science, Inc.Xcopri | $18,557 | $175,819133 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $154 | $54,82233 claims |
| AbbVieQulipta | $183 | $18,14816 claims |
| PfizerNurtec Odt | $1,544 | $16,09311 claims |
| Eisai Inc.Fycompa | $484 | $14,65111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 270 neurology providers in South Carolina.
Other neurology in Mt Pleasant
- Charles KellyMt Pleasant$30K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
- Thomas HughesMt. Pleasant$102K
- Kathleen WoschkolupGreenville$97K
- Sarah BreevoortCharleston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.